Home services

Uber To Reopen San Francisco Workplaces With 20% Capability On March 29: Reuters


TPG selects banks for $ 594 million Asian Pathology IPO

(Bloomberg) – TPG Capital Asia has selected banks to prepare for an initial public offering of its pathology business in the region, which, according to knowledgeable people in Singapore, could raise up to S $ 800 million ($ 594 million) in Singapore. The private equity firm works with Citigroup Inc. and CIMB Group Holdings Bhd. The planned first-time share sale of Pathology Asia Holdings Pte. Ltd. Credit Suisse Group AG and DBS Group Holdings Ltd. are also working on the offer. They didn’t want to be named as the process is private. A listing in the city-state could take place at the end of this year, according to the respondents. Pathology Asia joins the renewable energy company Sunseap Group Pte, the brewery of Thai Beverage Pcl and the UK real estate investment of City Developments Ltd. if you trust in an IPO in Singapore. According to Bloomberg, the country has only seen one new listing this year. Aztech Global Ltd. raised approximately $ 224 million in one offer this month. Deliberations are ongoing and the size and timing of the IPO could change, respondents said. Representatives from Citi, CIMB, Credit Suisse, DBS and TPG declined to comment. TPG reached out to potential advisors for suggestions on the pathology unit’s IPO, Bloomberg News reported earlier this month. The buyout company expanded the business of its first 39 pathology laboratories, TPG 2018 from Healthscope Ltd. for A $ 279 million ($ 212 million), said a person familiar with the matter. It’s now worth about $ 2 billion, the person said. TPG Capital Asia manages approximately $ 9.9 billion in assets, according to its website. The branch of the global buyout company TPG has offices in Beijing, Hong Kong, Melbourne, Mumbai and Singapore. Pathology Asia Holdings, originally a result of the acquisition of Healthscope, comprises the Quest Laboratories brand in Singapore and Vietnam and Gribbles Pathology in Malaysia. There was the takeover of Singapore’s Innovative Diagnostics Pte. Known in 2018 and bought a minority stake in Australian drug testing company Safe Work Laboratories Pty the following year. More articles like this can be found at bloomberg.com. Subscribe to us now to stay ahead of your trusted source of business news. © 2021 Bloomberg LP

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button